AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
Australian clinical-stage radiopharmaceutical company AdvanCell has announced an expansion to the scope and breadth of its ...
We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly ...
Hosted on MSN8d
AdvanCell raises $112m as radiopharma buzz continuesAdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly ...
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...
SYDNEY, February 03, 2025--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback